Vignesh Rajah - Mar 5, 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Signature
/s/ John LaRocca, Attorney-in-Fact
Stock symbol
YMAB
Transactions as of
Mar 5, 2024
Transactions value $
-$28,283
Form type
4
Date filed
3/7/2024, 05:02 PM
Previous filing
Jan 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Sale -$28.3K -1.71K -4.81% $16.53 33.9K Mar 5, 2024 Direct F1, F2
holding YMAB Common Stock 4.27K Mar 5, 2024 By Spouse and minor F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Nondiscretionary sale to cover tax liability associated with the vesting and settlement of restricted stock units.
F2 This transaction was executed in multiple trades at prices ranging from $16.52 to $16.555, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes 4,033 shares of common stock owned by Reporting Person's spouse and 233 held by Reporting Person's minor child. Reporting Person may be deemed to have a pecuniary interest in the securities due to family relationship.
F4 Reporting Person disclaims beneficial ownership of the securities reported and this report shall not be deemed an admission that Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act, as amended, or for any other purpose.